Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
复制标题
DOI：
10.1007/s10637-010-9565-5
复制
发表时间：
2012-04
影响因子：
3.4
通讯作者：
Nakagawa, Kazuhiko
中科院分区：
文献类型：
--
作者：
Okamoto, Isamu;Shimizu, Toshio;Miyazaki, Masaki;Tsurutani, Junji;Ichikawa, Yasuko;Terashima, Masaki;Takeda, Masayuki;Fumita, Soichi;Ohki, Emiko;Kimura, Nobuyuki;Hashimoto, Junichi;Nakagawa, Kazuhiko
背景 舒尼替尼是一种口服多靶点酪氨酸激酶抑制剂，作用于血管内皮生长因子和血小板衍生生长因子受体，以及其他受体类型。我们进行了一项可行性研究，以调查舒尼替尼联合培美曲塞治疗晚期难治性实体瘤的安全性。方法 舒尼替尼按照连续每日给药 (CDD) 方案（37.5 mg/天）或 2 周停药 1 周的治疗方案（50 mg/天，方案 2/1）每天给药一次，并在重复 21 天周期的第 1 天与培美曲塞 500 mg/m2 联合给药。结果 12 名患者参加了该研究：其中 6 名患者参加 CDD 计划，6 名患者参加计划 2/1。接受治疗的患者均未出现剂量限制性毒性。毒性是可控的，并且与舒尼替尼和培美曲塞单药治疗研究中观察到的毒性类型相似。药代动力学分析没有揭示任何实质性的药物相互作用。一名鳞状细胞肺癌患者表现出部分缓解，五名患者病情稳定。结论 按照时间表 2/1（50 mg/天）或 CDD 时间表（37.5 mg/天）施用的舒尼替尼与标准剂量培美曲塞（500 mg/m2）的联合治疗对于既往接受过治疗的晚期实体瘤患者具有良好的耐受性。
Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors. Methods Sunitinib was administered once daily on a continuous daily dosing (CDD) schedule (37.5 mg/day) or a 2-weeks-on, 1-week-off treatment schedule (50 mg/day, Schedule 2/1) in combination with pemetrexed at 500 mg/m2 on day 1 of repeated 21-day cycles. Results Twelve patients were enrolled in the study: six on the CDD schedule and six on Schedule 2/1. None of the treated patients experienced a dose-limiting toxicity. Toxicities were manageable and similar in type to those observed in monotherapy studies of sunitinib and pemetrexed. Pharmacokinetic analysis did not reveal any substantial drug–drug interaction. One patient with squamous cell lung cancer showed a partial response and five patients had stable disease. Conclusions Combination therapy with sunitinib administered on Schedule 2/1 (50 mg/day) or a CDD schedule (37.5 mg/day) together with standard-dose pemetrexed (500 mg/m2) was well tolerated in previously treated patients with advanced solid tumors.
登录
查看更多内容
影响因子：
45.3
作者：
Burstein, Harold J.;Elias, Anthony D.;Miller, Kathy D.
通讯作者：
Miller, Kathy D.
影响因子：
5.8
作者：
Morabito, Alessandro;De Maio, Ermelinda;Perrone, Francesco
通讯作者：
Perrone, Francesco
DOI：
10.1007/978-3-642-01222-8_6
发表时间：
2010-01-01
期刊：
SMALL MOLECULES IN ONCOLOGY
影响因子：
--
作者：
Heng, Daniel Y. C.;Kollmannsberger, Christian
通讯作者：
Kollmannsberger, Christian
影响因子：
8.4
作者：
George, S.;Blay, J. Y.;Demetri, G. D.
通讯作者：
Demetri, G. D.
影响因子：
3
作者：
Britten, Carolyn D.;Kabbinavar, Fairooz;Slamon, Dennis
通讯作者：
Slamon, Dennis